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Can medical therapy mimic the clinical efﬁcacy or physiological
effects of bariatric surgery?
AD Miras1 and CW le Roux2
The number of bariatric surgical procedures performed has increased dramatically. This review discusses the clinical and
physiological changes, and in particular, the mechanisms behind weight loss and glycaemic improvements, observed following
the gastric bypass, sleeve gastrectomy and gastric banding bariatric procedures. The review then examines how close we
are to mimicking the clinical or physiological effects of surgery through less invasive and safer modern interventions that
are currently available for clinical use. These include dietary interventions, orlistat, lorcaserin, phentermine/topiramate,
glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, pramlintide, dapagliﬂozin, the duodenal–jejunal
bypass liner, gastric pacemakers and gastric balloons. We conclude that, based on the most recent trials, we cannot fully mimic
the clinical or physiological effects of surgery; however, we are getting closer. A ‘medical bypass’ may not be as far in the future
as we previously thought, as the physician’s armamentarium against obesity and type 2 diabetes has recently got stronger
through the use of speciﬁc dietary modiﬁcations, novel medical devices and pharmacotherapy. Novel therapeutic targets
include not only appetite but also taste/food preferences, energy expenditure, gut microbiota, bile acid signalling,
inﬂammation, preservation of b-cell function and hepatic glucose output, among others. Although there are no magic
bullets, an integrated multimodal approach may yield success. Non-surgical interventions that mimic the metabolic beneﬁts of
bariatric surgery, with a reduced morbidity and mortality burden, remain tenable alternatives for patients and health-care
professionals.
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INTRODUCTION
Obesity is an increasingly prevalent worldwide health problem.
Approximately one-third of US adults are obese, and obesity
rates have increased dramatically in the past 20 years.1
The health consequences of obesity are numerous, with
attendant increases in the risk of coronary heart disease, type
2 diabetes mellitus (T2DM), hypertension, dyslipidemia, stroke
and certain cancers.2 Speciﬁc causes are still unclear; however,
it is likely that a combination of metabolic, genetic, psychological
and environmental factors all contribute to the obesity
epidemic.
The number of bariatric surgical procedures performed has
also increased dramatically. The appropriate use of bariatric
surgery remains a subject of debate, with many physicians in the
ﬁeld remaining sceptical about it, in view of the risks associated
with surgery. Ultimately, less invasive treatments are needed to
address obesity and associated T2DM in a wider population of
affected individuals. This review will discuss the clinical and
physiological changes observed following bariatric surgery and
examine how close we are to mimicking them through less
invasive and potentially safer interventions. We have limited our
discussion to the most modern non-surgical treatments that are
currently available for clinical use in Europe and/or the in United
States.
METHODS
The source was a PubMed search used to identify relevant literature to the
clinical efﬁcacy and physiological effects of bariatric surgery procedures,
lifestyle interventions, modern pharmacotherapy and less invasive devices
on both obesity and T2DM. In view of the wide scope of the review,
preferably randomised controlled clinical trials (RCTs) and deﬁnitive basic
and clinical science publications were chosen with a particular focus to
those published 2009–2013.
Types and clinical effectiveness of bariatric surgery
Bariatric surgery has been shown to be the most effective treatment for
obesity and T2DM, both in large well-matched clinical studies and RCTs.3–8
Roux-en-Y gastric bypass (RYGB) and the adjustable gastric band (AGB) are
the most commonly performed surgical procedures around the world. The
RYGB procedure typically involves fashioning a 15- to 20-ml gastric pouch
and creating a large new outlet that rapidly empties into the mid small
intestine (Figure 1). The continuity of the bowel is restored via a jejuno–
jejunal anastomosis, between the excluded biliopancreatic limb and the
alimentary limb, performed 75–150 cm distally to the gastrojejunostomy.9
The gastric remnant is no longer exposed to food; gastric, pancreatic and
biliary secretions still ﬂow undiluted in the biliopancreatic limb and come
in contact with food in the jejuno–jejunal anastomosis. It is normally
performed laparoscopically and causes 25–30% weight loss, which is
maintained for at least 20 years.4,10
The AGB technique involves the insertion of an adjustable silicone ring
around the proximal aspect of the stomach, immediately below the
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gastro–oesophageal junction creating a small proximal pouch. The volume
of ﬂuid in the band is adjusted through injections in a subcutaneous port.
The procedure results in 20–25% long-term weight loss.10,11 The vertical
sleeve gastrectomy (VSG) is fashioned through the reduction in gastric
volume by the laparoscopic removal of 70–80% of the stomach. Previously,
VSG was performed as part of the duodenal switch procedure but is
increasingly used as a stand-alone procedure that can cause a weight loss
of 20–30% in the long term.12 Owing to increased rates of postoperative
and nutritional complications, the biliopancreatic diversion and duodenal
switch procedures are performed less frequently compared with the other
procedures.10,11
Bariatric surgery also results in signiﬁcant glycaemic improvements in
T2DM. Four RCTs have compared RYGB, AGB, VSG and biliopancreatic
diversion to lifestyle and pharmacological interventions for obese patients
with T2DM.5–8 Their results are consistent in that each of the procedures
was superior to non-surgical therapies in terms of reductions in weight,
glycaemia and glucose-lowering medication use.
The beneﬁts of bariatric surgery extend beyond improvements in
weight and glycaemic control; patients also exhibit reductions in
overall and cardiovascular morbidity and mortality rates, as well as a
reduction in cancer incidence.3,4,13 Although some early improvements
in diabetic retinopathy and nephropathy have been observed,14 the
long-term impact of bariatric surgery on microvascular complications is
not known. Currently, there are no data from RCTs to support the use of
surgery for comorbidities that are frequently associated with obesity
including non-alcoholic fatty liver disease, subfertility, renal disease and
functional impairment. In terms of obstructive sleep apnoea, AGB
resulted in greater weight loss but did not improve the apnoea
hypopnoea index signiﬁcantly more than non-surgical weight loss
therapies.15 In the absence of sufﬁcient evidence, the choice of
technique depends on patient and multidisciplinary team preference,
local expertise and funding.
Complications of bariatric surgery
As with any intervention, bariatric surgery is not without complications.
The most serious complications associated with bariatric surgery include
postoperative sepsis, anastomotic leaks, bleeding and venous thromboem-
bolism, including fatal pulmonary embolism.16 The risk of early mortality after
bariatric surgery ranges from 0.1 to 2.0% depending on the procedure.10 The
longitudinal assessment of bariatric surgery consortium reported a 30-day
postoperative mortality rate of 0.3% with RYGB.17 Factors associated with
increased mortality include male gender, age older than 65 years, reduced
cardiorespiratory ﬁtness levels and limited surgeon experience.16
Long-term nutritional deﬁciencies may occur in some bariatric surgery
patients due to changes in the anatomy of the gastrointestinal tract with
surgery.18 Deﬁciencies in vitamin B12, folate and iron are not uncommon
early after surgery and evidence of calcium, vitamin D and trace element
deﬁciencies can also occur months to years after the procedure.18
Although bariatric surgery has known beneﬁcial effects in terms of T2DM
remission, it may result in recurrent postprandial hypoglycaemia in some
patients, which may signal an extreme metabolic reaction to surgery. The
Swedish bariatric surgery registry found that the risk of hypoglycaemia and
related diagnoses were higher in bariatric surgery patients compared with
the general population, although the absolute risk of these events
remained small.19
Overall, modern bariatric surgery has an acceptable risk/beneﬁt proﬁle,
with careful patient selection and the availability of an appropriately
experienced multidisciplinary team that is responsible for patient care in
both the preoperative and postoperative periods.
Appetite, energy expenditure and food preferences after bariatric
surgery
Although RYGB was originally designed to cause gastrointestinal restriction
and malabsorption, an increasing volume of evidence supports that the
Figure 1. Anatomical manipulation of the surgical bariatric procedures. Bariatric procedures: (a) Roux-en-Y gastric bypass; (b) adjustable
gastric banding; (c) vertical sleeve gastrectomy; (d) biliopancreatic diversion; (e) biliopancreatic diversion with duodenal switch.
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surgery works by reducing hunger and increasing satiation after a meal.20
A number of studies suggest that diet-induced energy expenditure
increases after RYGB, further aiding weight loss.21,22 Patients also witness a
healthy shift in eating behaviour, away from calorically dense high-fat and
sweet food to low-calorie alternatives.23 The mechanisms behind this are
not fully clear yet but may include alterations in food reward, changes in
taste function or other consequences relating to the dumping
syndrome.24,25 Contrary to malabsorptive procedures, such as the
biliopancreatic diversion and duodenal switch, RYGB results in minimal
fat and no carbohydrate malabsorption.26,27
There is intense interest in the mechanisms through which VSG and AGB
work. Following VSG, patients report reductions in appetite to those
experienced after RYGB.28 Energy expenditure appears to remain either
stable or shows a tendency to decrease in animal models of VSG.29,30 In
terms of the AGB, higher intraluminal pressure on vagal afferents in the
stomach may facilitate reductions in hunger and meal size after AGB.31,32
Food choices may either not change or even deteriorate,33 whereas energy
expenditure has not been quantiﬁed after AGB.
Gut hormones are some of the mediators of reduced hunger, increased
satiation and consequent weight loss after RYGB and VSG surgery.
Speciﬁcally, RYGB and VSG have been shown to enhance meal-stimulated
hormonal secretion of anorexigenic insulin, peptide tyrosine tyrosine (PYY),
glucagon-like peptide 1 (GLP-1),20,28,34 which is sustained for at least 10
years (in the case of RYGB).35 The rise in levels of these hormones after VSG
is intriguing, but may be because of increased gastric emptying, propelling
nutrients to the mid and distal intestine.36 The AGB does not signiﬁcantly
alter the plasma levels of these hormones.20,37
Owing to the variability in the laboratory techniques used to measure
orexigenic ghrelin, it is currently unclear what happens to this hormone
after RYGB;38 however, reasonable evidence exists that it decreases after
VSG and increases after AGB.39 Obestatin, which is a hormone produced
from the ghrelin gene but has anorexigenic action and antagonises the
effects of ghrelin, has been shown to increase after VSG but remains
unaltered after RYGB.40
Plasma leptin levels are decreased by all the three procedures; however,
this is not followed by the compensatory changes in eating behaviour that
accompany diet-induced weight loss. The increase in anorexigenic gut
hormones seen after RYGB and VSG and the increased vagal stimulation
after AGB appear to be enough to counterbalance the effects of lower
leptin levels on hunger and weight regain. There is no evidence from
animal models to suggest that leptin sensitivity is improved beyond that
expected for weight loss per se.29
More recently, other novel mediators that may contribute to weight loss
have surfaced. In a series of very elegant experiments, the transfer of gut
microbiota from mice that have undergone RYGB to germ-free mice leads
to 5% weight loss in the latter group, potentially through altered short-
chain fatty acid production and signalling.41
T2DM after bariatric surgery
Beta cell function. All bariatric surgery procedures cause glycaemic
improvements through weight loss per se; however, improvements are
more pronounced after RYGB and VSG and start becoming apparent
before weight loss.42,43 A potential reason underlying this may be the
improvements in b-cell function after these procedures. After both RYGB
and VSG, the early postprandial release of insulin is increased within a few
days after surgery but also remains exaggerated after weight loss has been
achieved.44–47 On the contrary, total insulin release (expressed as area
under the curve) is appropriately reduced after weight loss and in the face
of reduced peripheral insulin resistance.45 AGB results in gradual weight
loss and appropriate reductions in total postprandial insulin release but
without the exaggerated early responses seen after RYGB or VSG.45
A human mechanistic study has shown that the early increases in insulin
release after RYGB is partly because of the incretin effect of GLP-1.48
However, it has also been suggested that the negative energy balance
achieved after bariatric surgery may be partly responsible for the early
marked improvement of b-cell function.49. Even though this theory may
well apply in the context of calorie intake reduction after bariatric surgery,
it does not explain the very different insulin release proﬁles between
RYGB/VSG and AGB.
Insulin resistance. The RYGB, AGB and VSG procedures facilitate reduc-
tions in peripheral insulin resistance directly as a result of gradual weight
loss.50 Interestingly, however, in some human studies, hepatic insulin
resistance, is reduced within days after RYGB before any signiﬁcant weight
loss has taken place.51,52 Whereas this may be a direct result of a negative
energy balance,49 the reduction in hepatic insulin resistance in some
studies is greater in patients after RYGB compared with patients
undergoing similar caloric restriction after AGB or a very-low-calorie
diet.44,51,52 Even though these ﬁndings are not universal, they suggest that
the bypass of the proximal bowel may have caloric intake and weight loss-
independent effects on hepatic insulin resistance and hepatic glucose
output.
Gut nutrient sensing. The role of portal vein glucose sensing became
apparent in an elegant study of animal models that underwent a modiﬁed
bypass procedure in which intestinal glucose production was increased
after surgery. This led to higher levels of glucose in the portal vein and
triggered a neural cascade through afferent and efferent vagal ﬁbres
resulting in lower hepatic glucose output.53 In animal models of the
duodeno–jejunal bypass, jejunal nutrient sensing has also been shown to
exert profound control on hepatic glucose output in a similar manner.54
Exposure of the jejunum to undigested nutrients following RYGB (and
perhaps VSG) may explain the reductions in hepatic glucose output seen
early surgery; however, such mechanistic studies have not been performed
in humans as yet.
Bile acids. The search for the mechanisms underlying weight loss and
glycaemic improvements after bariatric surgery is gradually revealing
numerous novel metabolic targets. Whereas gut hormones affect insulin
secretion after bariatric surgery, bile acids may also exert a signiﬁcant
physiological effect. Bile acids have been shown not only to increase gut
hormone production but also to reduce food intake, gluconeogenesis,
insulin resistance and even increase energy expenditure through their
actions on the FXR and TGR-5 receptors in the periphery and/or in the
brain.55 Plasma bile acids are elevated after RYGB and VSG, but not AGB,
and negatively correlate with post-prandial glycaemic excursions.56,57
However, no mechanistic studies have clearly deﬁned their role after RYGB
or VSG so far.
Table 1 summarises the available evidence on the physiological changes
that take place after bariatric surgery.
Lifestyle modiﬁcation
Appetite reduction is a compelling goal for long-term weight loss and the
resolution of the metabolic effects of morbid obesity. The appeal of
abundant highly palatable food that inﬂuences eating patterns can make
caloric restriction an unachievable goal for many individuals. In obese
patients who have achieved weight loss, clinical data suggest the presence
of compensatory mechanisms that may lead to weight regain.58 One study
reported that overweight and obese patients who underwent a 10-week
weight loss programme had signiﬁcantly lower levels of leptin, PYY, CCK,
insulin and amylin and signiﬁcant increases in ghrelin levels from baseline.
These differences persisted at 1 year and were accompanied by signiﬁcant
increases in appetite and preoccupation with food.58
Therefore, once weight loss has been achieved, appetite control is
critical to prevent subsequent regain of weight. The effect of nutrient
content on weight maintenance was examined in overweight or obese
adults who had achieved at least an 8% reduction in body weight with a
very-low-calorie diet.59 Individuals who completed a high-protein, low-
glycaemic index diet regimen for 26 weeks following initial weight loss
exhibited a higher maintenance rate of weight loss compared with those
who completed a low-protein, high-glycaemic index diet. Furthermore,
individuals assigned to the high-protein, low-glycaemic index diet
continued to lose weight over the course of the study, whereas
participants assigned to the low-protein, high-glycaemic index diet
demonstrated signiﬁcant weight regain. Diets high in protein and low in
carbohydrates appear to be superior in the reduction of hunger and their
ketogenic effects may have a role.60
In the context of T2DM, a very-low-calorie diet of 600 kCal had
impressive short-term effects in reducing peripheral and hepatic insulin
resistance, hepatic glucose output, and liver and pancreatic triacylgly-
cerol.49 The diet also led to improvements in b-cell function and the
authors concluded that part of the pathophysiology of T2DM can be
reversed by energy intake restriction. This study sent a positive message to
patients; however, the long-term success rate of such a strict dietary
modiﬁcation remains uncertain. However, even with little or no
weight loss, high-protein, low-carbohydrate, low-glycaemic index and
Mediterranean diets can also reduce cardiovascular risk or events in
patients with or without T2DM.61,62 More recently, the LOOK AHEAD RCT
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reported that intensive lifestyle modiﬁcation, including only moderate
caloric restriction, resulted in higher rates of T2DM remission at 4 years
(7.3%) compared with standard education (2.0%).63 Even though the
authors commented that these rates were low in absolute terms and did
not translate in superior improvements in cardiovascular outcomes,64 the
patient population was relatively old, had long T2DM duration and the
criteria used for remission were stringent. These results suggest that early
and intensive lifestyle intervention in T2DM can have positive effects and
even obviate the need for medications in some patients for a reasonable
length of time during the course of the disease.
Obesity pharmacotherapy
The ability to achieve weight loss and maintenance with pharmacological
agents has been an attractive yet elusive goal. For instance, although drugs
such as rimonabant and sibutramine were previously used as a
pharmacological strategy for obesity management, these agents were
withdrawn following reports of increased risks of psychological and
cardiovascular adverse events, respectively.65,66 The discontinuation of
these medications has not only led to longer and more thorough
assessment of adverse events before and after drug marketing but also
hopefully to the development of weight-loss agents that are more
selective in their mode of action either in the brain or in the periphery.
Orlistat is the only drug that has stood the test of time in many countries
around the world. It decreases fat absorption by 30% through the
inhibition of pancreatic and gastric lipase. In practice, it works by making
patients consciously reduce their fat intake to avoid unpleasant and
socially embarrassing oily diarrhoea. A number of RCTs and meta-analyses
have shown small decreases in weight of 2.9 kg,67 with beneﬁcial effects on
cardiometabolic risk factors and reductions in the incidence of T2DM.68
Gastrointestinal side effects remain common, whereas the rare occurrence
of severe liver injury has also been reported.67
After 13 years with no new drug approvals, in 2012 the US FDA
sanctioned two agents that reduce appetite and lead to modest weight
loss. Lorcaserin is a serotonin 2C (5-hydroxytryptamine [5-HT]2c) agonist
that leads to reductions in food intake and perhaps food reward. The
5-HT2C receptor is not only located in the hypothalamus but also in some
of the reward areas of the brain, including the prefrontal cortex, nucleus
accumbens and amygdala. Phase 3 trials of 52-week duration have
demonstrated that patients on the 10-mg, twice-daily dose lose an extra
2.9–3.6% of weight compared with patients on placebo.69–71 This was also
accompanied by a 0.5% absolute decrease in HbA1c, improvements in
lipids, blood pressure and waist circumference and no signiﬁcant increase
in the rate of cardiac valvular disease compared with placebo. The most
frequent side effects of headache, dizziness, dry mouth and nausea were
mild and tolerated by most patients, whereas symptomatic hypoglycaemia
was reported signiﬁcantly more frequently by diabetic patients in the
intervention compared with the placebo arm.
The combination of phentermine and the antiepileptic topiramate has
also been recently approved by the US FDA. Phentermine is a
sympathomimetic drug, and its use with fenﬂuramine was discontinued
in 1997 because of the association of fenﬂuramine with cardiac valvular
disease and pulmonary arterial hypertension. Topiramate attenuates
appetite through mechanisms that remain to be elucidated. The high-
dose combination of the two medications led to an impressive 7.5–8.7%
placebo-adjusted weight loss, a 0.4% absolute reduction in HbA1c and a
decrease in the incidence of T2DM at 2 years compared with placebo.72–74
Side effects included paraesthesiae, constipation and dry mouth. Even
though small increases in heart rate (by 1.7 beats per min, but no adverse
clinical events) and discontinuation of the drug because of depression/
anxiety and cognitive impairment were observed, the use of controlled
release topiramate and lower doses of phentermine, as a ﬁxed dose
combination, may reduce the incidence of these potentially serious and
problematic adverse events. The drug’s longer-term effects on
cardiovascular and psychiatric morbidity remain to be determined.
In summary, the two novel centrally acting medications may mimic in
part the effect of bariatric surgery in reducing hunger; however, certainly
their initial use should be cautious, and close long-term patient monitoring
is essential.
Modern T2DM pharmacotherapy
The drug discovery output for T2DM drugs has been much more fruitful
and successful, mainly owing to the use of gut hormone analogues, which
mimic endogenously produced ‘natural’ signals, rather than entirely
synthetic agents with potentially diffuse receptor afﬁnity.
GLP-1 receptor agonists. Apart from its anorexigenic effects, GLP-1 acts as
an incretin hormone to increase insulin release and lower glucagon
secretion and hepatic glucose output.75 The four available GLP-1 receptor
agonists are the short-acting exenatide twice-daily (BID) and lixisenatide,
and the longer-acting exenatide extended release (ER) and liraglutide once
daily. Head-to-head trials between exenatide BID and ER have shown the
superior efﬁcacy of the once-weekly preparation, which in addition to oral
therapy, reduced HbA1c by 1.6–1.9% and weight by 2.3–3.7 kg compared
with respective absolute reductions of 0.9–1.5% and 1.4–3.6 kg with
exenatide BID.76,77 Trials comparing liraglutide with exenatide BID in
addition to oral therapy have shown that at a dose of 1.8mg liraglutide
was more effective in reducing HbA1c (absolute reduction 1.12% versus
0.79%) but not weight ( 3.2 versus  2.8 kg; not signiﬁcant).78 These
medications reduce blood pressure in a weight-independent manner and
even improve b-cell function as assessed by the homoeostasis model
assessment of b-cell function and proinsulin/insulin ratio.79,80 The superior
efﬁcacy of liraglutide may be because of its lower immunogenicity.81
Lixisenatide was the last GLP-1 receptor agonist to be launched in the
market. On the basis of the data from the GetGoal programme of clinical
trials, it leads to placebo-controlled HbA1c reductions of 0.3–0.9% (starting
HbA1cB8.0–8.5%) and weight changes of  2.7 to þ 0.3 kg (starting body
mass index B30–34 kgm 2).82,83 Lixisenatide is particularly effective in
controlling postprandial glucose excursions and may therefore be clinically
useful when used in combination treatment with long-acting insulins.
Whereas these compounds are currently used in the management of
T2DM, an expanded role of high-dose liraglutide in weight-loss initiation
and maintenance is currently under investigation.84
A major advantage of these drugs is their relatively favourable side
effect proﬁle. On the basis of the trials mentioned previously, the rates of
hypoglycaemia are relatively low, whereas nausea, vomiting and diarrhoea,
although common, are well tolerated by most patients. Nausea tends to be
transient in the majority of cases and is less common with the longer-
acting preparations.84 Longer-term studies are necessary to determine
cardiovascular and safety outcomes, and in particular, answer speciﬁc
concerns over the association with pancreatitis, pancreatic and thyroid
C-cell cancer, and increases in heart rate with exenatide and liraglutide.
DPP-4 inhibitors. The four available dipeptidyl peptidase-4 (DPP-4)
inhibitors are sitagliptin, vildagliptin, saxagliptin and linagliptin. They all
inhibit the enzyme that degrades GLP-1, thus raising the tissue levels. The
major advantage of these medications is their oral route of administration
and the relatively low incidence of hypoglycaemia and gastrointestinal
side effects. Compared with GLP-1 agonists, they are less effective in
improving glycaemia (HbA1c absolute reductions of 0.5–1.0%) and are
weight neutral.85 It is interesting to note that DPP-4 inhibitors are only
slightly less efﬁcacious compared with GLP-1 agonists, even though
plasma levels while on DPP-4 treatment are signiﬁcantly lower to those
seen when on GLP-1 analogue therapies. A number of elegant studies have
shown that the majority of physiological action of DPP-4 inhibitors is
exerted through local, and not just plasma, increases in GLP-1 and
stimulation of the gut wall and portal vein vagal receptors.86,87 As DPP-4 is
also necessary for the activation of anorexigenic gut hormones, such as
PYY, its inhibition may be responsible for the weight neutrality of these
agents.
Amylin mimetics. Pramlintide is an injectable amylin-mimetic that has
been approved by the FDA for the treatment of T1DM and T2DM. Amylin is
a hormone co-secreted with insulin by the b cell and has multiple
physiological actions including the reduction in gastric emptying, food
intake, post-prandial glucose and glucagon release. In the context of
T2DM, it has been shown to cause small placebo-subtracted absolute
reductions in HbA1c of 0.2–0.4% (even with high starting HbA1c of
8.2–9.3%) and weight loss of 2.1–2.3 kg (starting weight 97–103 kg).88 Side
effects include temporary nausea and mild to moderate hypoglycaemia in
T2DM. Its high cost and injectable mode of delivery have somewhat
limited its clinical use.
SGLT-2 inhibitors. The newest class of agents released for clinical use in
some parts of the world is the sodium-glucose co-transporter 2 inhibitors
that lower plasma glucose, independently of insulin resistance and
secretion, by reducing renal reabsorption.89 The placebo-subtracted
absolute reductions in HbA1c with the ﬁrst agent of this class,
dapagliﬂozin, are modest (0.4–0.8%, starting HbA1c B7.8–8.0%), but are
maintained at least up to 2 years, whereas the excretion of glucose is
beneﬁcial for weight loss (2.0–3.0 kg).89 Dapagliﬂozin also leads to
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reductions in systolic blood pressure of 4–5 and diastolic blood pressure of
2–3mmHg, partially as a result of its diuretic effects and the inhibition
of the renin–angiotensin system in the kidney. The route of administration
of dapagliﬂozin is oral and the rates of hypoglycaemia with the drug are
low. The major beneﬁt of this class of drugs is that they can be used at any
stage of the disease process, in combination with most other glucose-
lowering medications, and may even preserve beta cell function. Adverse
effects include urinary tract and genital infections and volume depletion,
and there are concerns regarding the rare incidence of breast and bladder
cancer and liver injury.89
In summary, the treatment of T2DM has undergone a metamorphosis in
the last 7 years or so because of the addition of a number of new classes of
glucose-lowering medications. These not only have reasonable effects on
glycaemia but, more importantly, promote clinically signiﬁcant weight loss.
However, long-term data on cardiovascular outcomes and serious adverse
events are vital before these agents’ position in the treatment algorithm
for T2DM is secure.
Devices
The most promising of the devices currently in use as less invasive
treatments for obesity and T2DM is the duodenal–jejunal bypass liner
(EndoBarrier, GI Dynamics, Lexington, MA, USA). It is made of a plastic
polymer, is 60 cm in length and is inserted endoscopically in such a way as
to line the proximal small bowel and exclude contact of food with its walls.
By mimicking the physiological changes in the biliopancreatic limb (one of
the components of RYGB), this device leads to weight reductions of
10–20%.90,91 Its metabolic effects are more impressive, with absolute
reductions in HbA1c of B1.2–2.3% (starting HbA1c 7.3–9.1%).92–94 The
device lowers fasting glucose within 1 week of insertion; however, the
mechanism of action remains unclear. The early glycaemic improvements
suggest beneﬁcial effects on hepatic insulin resistance and hepatic glucose
output. The exposure of the proximal small bowel to undiluted bile acids
and of the distal small bowel to undigested nutrients may have a vital
physiological role in the efﬁcacy of this device.54 The major limitations of
this intervention are that it has to be explanted electively at 6–12 months
and may need to be prematurely removed because of severe abdominal
pain, vomiting, obstruction and bleeding in up to 30% of cases. As with all
medical devices, it needs to undergo further comprehensive evaluation
through clinical trials before it is widely used in clinical practice.
Gastric stimulators, which are inserted endoscopically, work by reducing
hunger and increasing satiation. Their mode of action is unclear but may
include inhibition of efferent vagal signalling resulting in gastric detention,
reduced gastric emptying and therefore early satiation.95 They may also
have stimulatory effects on afferent vagal ﬁbres, which signal satiation to
the hypothalamus via the brainstem. Even though open-labelled studies
reported promising results, the ﬁndings from RCTs have been less
encouraging.96 Nevertheless, there is room for the technology to
improve and promote weight loss more safely than bariatric surgery.
Gastric balloons are ﬂuid-ﬁlled silicone sacs inserted endoscopically and
reduce weight by increasing early satiety. The current published studies
have not shown their superiority to conventional weight-loss treatments.97
However, gastric balloons can still be useful as a temporary measure to
reduce anaesthetic risk and therefore act as a bridge to elective
orthopaedic, bariatric, cardiac or transplantation surgery.
DISCUSSION AND CONCLUSION
So can we mimic the clinical efﬁcacy of surgery with less invasive
therapies? On the basis of the most recent studies, the answer is
that at the moment we cannot, but we are getting closer. The SOS
study compared bariatric surgery to lifestyle and behavioural
interventions. The study started recruiting patients in 1987, and
modern obesity pharmacotherapy was not approved in Sweden
until 1998. Additionally, the lifestyle support that patients received
was very heterogeneous and in some cases not intensive at all.
Nevertheless, weight loss and glycaemic improvement outcomes
were far better with surgery, even after 20 years of follow-
up.3,4,98,99
The most recent RCTs, which have focused on patients with
T2DM, tell a slightly different story. In a head-to-head trial
between biliopancreatic diversion, RYGB and modern medical
care, the surgical groups did better in terms of glycaemic control
and weight loss than the medically treated group, but to a lesser
degree when compared to the SOS study.5 Medical patients lost
4.7% of weight, their HbA1c improved by 8.4% (relative reduction)
and the blood pressure and lipid outcomes were not statistically
different compared with the RYGB group at 24 months. In an RCT
that compared RYGB with VSG and modern medical care, the
patients in the latter group also lost weight, improved their
glycaemic control, cardiometabolic factors and inﬂammation at
12 months.6 Whereas surgery was still superior to medical care,
the combination of the two was synergistic in its positive
outcomes. Even though the combination of surgical and non-
surgical interventions has been practiced successfully for years in
other ﬁelds of metabolic and endocrine medicines (for example,
pituitary disease), the concept of providing bariatric surgery as part
of a treatment algorithm, together with—and not instead of—less
invasive therapies is novel and one that is increasingly popular.6,8
The most up-to-date lifestyle modiﬁcation therapies, pharma-
cotherapy and medical devices were only partially studied in these
trials. A ‘medical bypass’ alternative to bariatric surgery may not
be as far in the future as we previously thought. Weight loss of
signiﬁcant magnitude could potentially be achieved through the
use of lorcaserin, phentermine/topiramate, orlistat, gut hormone
analogues and medical devices, not in isolation but in combina-
tion. In the context of T2DM associated with obesity, we would
suggest that the effect of RYGB on reducing hepatic insulin
resistance can be mimicked by the endoscopically placed
duodenal–jejunal bypass liner and that some of the effect of
RYGB on enhanced insulin secretion can be mimicked by GLP-1
agonists. In addition, there may be a synergism to reduce body
weight between the endoscopically placed duodenal–jejunal
bypass liner, GLP-1 agonists, DPP-4 inhibitors, pramlintide and
SGLT-2 inhibitors. The weight loss and glycaemic improvements
induced by these less invasive treatments could then be
maintained on a high-protein, low-glycaemic index or Mediterra-
nean diet. The clinical efﬁcacy and safety of such combination
therapies, together with gut hormone analogues and bile acid
receptor agonists currently under development, could be
compared with that of bariatric surgery in large-scale RCTs. These
trials will inform us as to whether the beneﬁcial clinical and
physiological effects of bariatric surgery can be mimicked but also
whether this can be achieved with a reduced morbidity and
mortality burden.
We conclude that the physician’s armamentarium against
obesity and associated T2DM is getting stronger through the
use of speciﬁc dietary modiﬁcations, novel medical devices and
pharmacotherapy. Although there are no magic bullets, an
integrated multimodal approach may yield success. Non-surgical
interventions that mimic the metabolic beneﬁts of bariatric
surgery remain tenable alternatives for many patients and
health-care professionals.
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